Nocion Therapeutics, Inc. a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced that preclinical data supporting the ...

Approximately 2% of patients with irritable bowel syndrome (IBS) have a mutation of the SCN5A gene that disrupts sodium channel function, according to a genotype analysis published online March 10 in ...